Publicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (187)

2024

  1. Advancing the fight against fibrosis in patients with heart failure: The contribution of sodium–glucose cotransporter 2 inhibition

    European Journal of Heart Failure

  2. Circulating biomarkers of myocardial remodelling: current developments and clinical applications

    Heart, Vol. 110, Núm. 19, pp. 1157-1163

  3. Consensus on the approach to hydrosaline overload in acute heart failure. SEMI/SEC/S.E.N. recommendations

    Revista Espanola de Cardiologia, Vol. 77, Núm. 7, pp. 556-565

  4. Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial

    Hypertension Research

  5. Myocardial fibrosis from the perspective of the extracellular matrix: Mechanisms to clinical impact

    Matrix Biology, Vol. 134, pp. 1-22

  6. Reassessing the management of hypertension: Time to prevent aldosterone-mediated heart failure

    European Journal of Heart Failure, Vol. 26, Núm. 2, pp. 195-198

  7. The implementation of cardionephrology in Spain is a health emergency

    Nefrologia, Vol. 44, Núm. 5, pp. 619-622

2023

  1. Biomarkers of Collagen Metabolism Are Associated with Left Ventricular Function and Prognosis in Dilated Cardiomyopathy: A Multi-Modal Study

    Journal of Clinical Medicine, Vol. 12, Núm. 17

  2. Cardiac Fibrosis in heart failure: Focus on non-invasive diagnosis and emerging therapeutic strategies

    Molecular Aspects of Medicine, Vol. 93

  3. Consensus document on palliative care in cardiorenal patients

    Frontiers in Cardiovascular Medicine, Vol. 10

  4. Growing Heart Failure Burden of Hypertensive Heart Disease: A Call to Action

    Hypertension, Vol. 80, Núm. 1, pp. 13-21

  5. Practical Patient Care Considerations With Use of Vericiguat After Worsening Heart Failure Events

    Journal of Cardiac Failure, Vol. 29, Núm. 3, pp. 389-402

  6. Prediction of Left Ventricular Reverse Remodeling and Outcomes by Circulating Collagen-Derived Peptides

    JACC: Heart Failure, Vol. 11, Núm. 1, pp. 58-72

  7. Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol

    Frontiers in Cardiovascular Medicine, Vol. 10

  8. Time to reconsider the perception and management of hypertensive heart disease

    European Journal of Heart Failure

2022

  1. A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

    Cancers, Vol. 14, Núm. 12

  2. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 24, Núm. 6, pp. 927-943

  3. Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 24, Núm. 6, pp. 944-958

  4. Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial

    ESC Heart Failure, Vol. 9, Núm. 6, pp. 4352-4357

  5. Failing Hypertensive Heart: a Question of Altered Telomere Biology?

    Hypertension, Vol. 79, Núm. 10, pp. 2185-2187